Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : The Thread Formerly Known as No Rest For The Wicked -- Ignore unavailable to you. Want to Upgrade?

To: Junkyardawg who wrote (8028)	1/16/1999 10:31:00 PM
From: Junkyardawg	Respond to of 90042

DD: Ticker: "LTEK" Look at the chart on this one: quote.yahoo.com 52wk low $29 3/8 52 wk high $40 3/4 Company Reports: LIFE TECH LIFE TECHNOLOGIES, INC. develops, manufactures and supplies more than 3,000 products used in life sciences research and commercial manufacture of genetically engineered products. The Company's products include sera, other cell growth media, biochemicals and enzymes and other biological products necessary for recombinant DNA procedures. These and related products and services provided by the Company are used in cellular biochemistry and molecular biology research and in the production of genetically engineered pharmaceuticals. Mkt Cap: $922.6 mm Shrs Out: 23.8 mm Float: 8.6 mm 3-Mth Ave Vol: 137 k 10-Day Ave Vol: 12 k Short Int: 0.0 mm Inst Own: 36.9 % Insider Own: 63.8 % P/E (ttm): 26.7 P/Sales (ttm): 2.6 Insider's Date 12/14/98 39.27 01/15/99 Bought 1,470,870 News: Getting bought out. More DD required. biz.yahoo.com dawg

To: Junkyardawg who wrote (8028)	1/16/1999 10:50:00 PM
From: Junkyardawg	Read Replies (1) \| Respond to of 90042

DD: Sub $5 stock. Ticker: "HIV" 52wk low $1 1/2 52wk high $6 1/2 Business Summary Cel-Sci Corporation is involved in the research and development of certain drugs and vaccines using the Company's proprietary cell culture technologies. HIV's first product, MULTIKINE, is being tested to determine if it is effective in improving the immune response of cancer patients. For the nine months ended 6/30/98, total income rose 28% to $483 thousand. Net loss fell 31% to $4.5 million. Results reflect higher interest income and the absence of license acquisition costs. Mkt Cap: $25.2 mm Shrs Out: 11.5 mm Float: 10.6 mm 3-Mth Ave Vol: 118 k 10-Day Ave Vol: 431 k Short Int: 0.4 mm Inst Own: 1.1 % Insider Own: 8.0 % P/E (ttm): -2.9 News: biz.yahoo.com dawg

To: Junkyardawg who wrote (8028)	1/17/1999 9:56:00 AM
From: kgreen	Read Replies (1) \| Respond to of 90042

HTV: I worked for HTV. Quite familiar with it and its management team. I own this stock. Very bullish on it. The managers from Hearst are very conservative broadcasters who make very sound decisions. They merged with the managers from Argyle who are very business savvy. Know how to gobble up a station and knock back its expenses. The pairing is one of the best management marriages I have ever witnessed. The only caveat about this company: this is a pure broadcast play unlike other media companies. The broadcast industry as a whole is seeing some weakness. I've watched the HTV numbers carefully and they look very solid. Just watch out for this next quarter. HTV took over some weak stations. It is certain to turn them around, but those weaker numbers could soften the books in the 1st quarter or two. I love this company and will be happy to provide you with any more information. Kath